Executive vice president Tony Kingsley leaves Biogen
pharmafile | October 22, 2015 | Appointment | | Biogen, John Cox, Tony Kingsley
Biogen has begun the search for a replacement for Tony Kingsley, former executive vice president of global commercial operations.
Kingsley will leave the company and a search has been initiated for a permanent replacement, Biogen says. In the interim his responsibilities will be assumed by John Cox, executive vice president of pharmaceutical operations and technology.
“Tony has made significant contributions to Biogen,” says George Scangos, Biogen’s chief executive. He led the successful introduction of five important new products and helped serve patients around the world with our life-transforming therapies. All of us wish Tony the best in his future endeavours.”
Kingsley joined Biogen in January 2010 as senior vice president of US commercial operations, and has been in his current position since November 2011. During his tenure, Biogen introduced five new therapies, including successfully launching Tecfidera (dimethyl fumarate), the most-prescribed oral treatment for multiple sclerosis today.
Biogen says his leadership contributed to the company’s revenue growth of 108% during his tenure. Prior to his time at Biogen, Tony served as senior vice president and general manager of the gynaecological surgical products business at Hologic, division president of diagnostic products at Cytyc, and was a partner at McKinsey and Company.
John Cox has served in his current position since June 2010. He joined Biogen in 2003 and has held several senior executive positions, including senior vice president of technical operations, senior vice president of global manufacturing, vice president of manufacturing, and general manager of Biogen’s operations in Research Triangle Park, North Carolina.
“We are pleased that John will lead our commercial operations on an interim basis,” Scangos continued. “His 12 years at Biogen and in-depth knowledge of our pharmaceutical and commercial operations give us great confidence that we will continue to execute on the commercial opportunities at-hand as we search for a permanent leader.”
Related Content
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose …
Biogen and Stoke report positive results for Dravet syndrome drug
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …
